Outcome of Board Meeting held on 11-02-2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.6 pts more than Nifty Microcap 250 and 0.7 pts more than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Jeevan Scientific Technology Limited's board approved its Q3 FY26 unaudited financial results (standalone and consolidated) along with the limited review report from auditor Pavuluri & Co, which issued an unmodified (clean) conclusion. On a standalone basis, Q3 revenue from operations jumped to Rs 1,690.66 lakhs, up about 42% from Rs 1,186.64 lakhs in Q3 last year, while standalone profit after tax surged to Rs 230.06 lakhs from Rs 32.25 lakhs. However, the nine-month standalone picture is weaker, with PAT at just Rs 5.53 lakhs versus Rs 207.28 lakhs a year ago. On a consolidated basis, Q3 revenue rose to Rs 1,907.15 lakhs (vs Rs 1,250.72 lakhs) and PAT was Rs 240.09 lakhs, but the 9-month consolidated result slipped into a loss of Rs 80.86 lakhs versus a profit of Rs 132.12 lakhs last year.
A strong sequential and year-on-year rebound in Q3 standalone profits is positive for sentiment, but the sharp slump in 9-month consolidated profitability suggests pressure building on margins or one-off costs earlier in the year. Investors should watch whether the Q3 momentum sustains into Q4 before drawing conclusions on full-year performance.